Breakthrough in Cancer Immunotherapy: Scalable Production of NK Cells Offers New Hope

Researchers in China have announced a significant advancement in cancer immunotherapy, developing a more efficient and scalable method for producing engineered natural killer (NK) cells. This breakthrough addresses key limitations in current CAR-NK therapy approaches, potentially paving the way for more accessible and affordable cancer treatments.

The Promise of NK Cell Immunotherapy

Natural killer (NK) cells are crucial components of the innate immune system, providing a rapid response to both viral infections and cancer. Unlike T cells, NK cells don’t require prior sensitization to recognize and destroy tumor cells, making them an attractive target for immunotherapy. [1] Chimeric antigen receptor (CAR)-NK therapy involves genetically engineering NK cells to express a CAR, enabling them to precisely target and eliminate cancer cells expressing a specific antigen.

Challenges with Traditional CAR-NK Cell Production

Traditional methods of generating CAR-NK cells have faced several hurdles. These include sourcing NK cells from peripheral blood or cord blood, which can be variable in quality and hard to modify efficiently. The process is often costly, time-consuming, and limited by the availability of donor cells. [2]

A Novel Approach: Stem Cell-Derived NK Cells

A team led by Professor Jinyong Wang at the Institute of Zoology of the Chinese Academy of Sciences has pioneered a new strategy. Instead of directly modifying mature NK cells, they start with CD34+ hematopoietic stem and progenitor cells (HSPCs) derived from cord blood. These cells are then induced to become induced NK (iNK) cells and CAR-engineered iNK (CAR-iNK) cells. [2] This approach, recently published in Nature Biomedical Engineering, overcomes many of the limitations associated with traditional methods.

Three-Step Expansion and Differentiation Process

The researchers developed a three-stage process to efficiently generate iNK and CAR-iNK cells:

• Stage 1: Expansion of HSPCs: CD34+ HSPCs (or CD19 CAR-transduced HSPCs) are expanded using irradiated AFT024 feeder cells, resulting in an 800- to 1,000-fold increase in cell numbers within 14 days.
• Stage 2: NK Lineage Commitment: Expanded cells are cultured with OP9 feeder cells to form hematopoietic organoid aggregates, promoting efficient commitment to the NK cell lineage.
• Stage 3: Maturation and Expansion: NK-committed cells are allowed to mature and further expand, yielding highly pure iNK or CAR-iNK cells expressing endogenous CD16.

Massive Cell Output and Reduced Costs

This new method demonstrates remarkable efficiency. A single CD34+ HSPC can generate up to 14 million iNK cells or 7.6 million CAR-iNK cells. Researchers estimate that a fifth of a typical cord blood unit could potentially produce enough cells for thousands of treatment doses. [2] the process significantly reduces the amount of viral vector needed for CAR engineering – approximately 1/140,000 to 1/600,000 less than traditional methods.

Promising Results in Leukemia Models

Laboratory testing has shown that both iNK and CAR-iNK cells exhibit potent tumor-killing activity. In preclinical models of human B-cell acute lymphoblastic leukemia (B-ALL), CD19 CAR-iNK cells effectively reduced tumor growth and prolonged survival in mice. [2]

Future Directions

This innovative approach to NK cell production holds significant promise for advancing cancer immunotherapy. By addressing the challenges of scalability and cost, it could make this potentially life-saving treatment more accessible to patients worldwide. Further research and clinical trials will be crucial to fully evaluate the safety and efficacy of these stem cell-derived NK cells in humans. [3], [4]